Xu et al. could show that the combination of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) and MWA in the treatment of non-small cell lung cancer (NSCLC) can result in significantly longer progression-free survival times and can achieve disease control rates of up to 85.7% compared to DEB-BACE alone [22]. This evidence concerns the gene BACE1 and non-small cell lung carcinoma.